Unknown

Dataset Information

0

XCT Inhibition Increases Sensitivity to Vorinostat in a ROS-Dependent Manner.


ABSTRACT: As histone deacetylase inhibitors (HDACIs) have limited efficacy against solid tumors, we investigated whether and how oxidative stress is involved in sensitivity to HDACIs to develop a novel therapeutic option of HDACIs treatment. We first tested whether a reduction of the antioxidant glutathione (GSH) by glutamine deprivation affects sensitivity to a commercially available HDACI vorinostat and reactive oxygen species (ROS) accumulation. Next we investigated the relationship between a glutamate-cystine transporter xCT and the efficacy of vorinostat using siRNA of xCT and bioinformatic analyses. Finally, we verified the combinatory effects of vorinostat and the xCT inhibitor salazosulfapyridine (SASP) on ROS accumulation, cell death induction, and colony formation. Glutamine deprivation increased vorinostat-mediated cell death with ROS accumulation. Genetic ablation of xCT improved the efficacy of vorinostat, consistent with the results of public data analyses demonstrating that xCT expressions positively correlate with insensitivity to HDACIs in many types of cancer cell lines. Vorinostat caused ROS accumulation when combined with SASP, possibly resulting in synergistic ferroptosis. Our study provides a novel mechanistic insight into the mechanism underlying sensitivity to HDACIs involving xCT, suggesting xCT to be a promising predictive marker of HDACIs and rationalizing combinatory therapy of HDACIs with xCT inhibitors to induce ferroptosis.

SUBMITTER: Miyamoto K 

PROVIDER: S-EPMC7226257 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

xCT Inhibition Increases Sensitivity to Vorinostat in a ROS-Dependent Manner.

Miyamoto Keiko K   Watanabe Motoki M   Boku Shogen S   Sukeno Mamiko M   Morita Mie M   Kondo Haruhito H   Sakaguchi Koichi K   Taguchi Tetsuya T   Sakai Toshiyuki T  

Cancers 20200330 4


As histone deacetylase inhibitors (HDACIs) have limited efficacy against solid tumors, we investigated whether and how oxidative stress is involved in sensitivity to HDACIs to develop a novel therapeutic option of HDACIs treatment. We first tested whether a reduction of the antioxidant glutathione (GSH) by glutamine deprivation affects sensitivity to a commercially available HDACI vorinostat and reactive oxygen species (ROS) accumulation. Next we investigated the relationship between a glutamate  ...[more]

Similar Datasets

| S-EPMC4165982 | biostudies-literature
| S-EPMC5342691 | biostudies-literature
| S-EPMC5633655 | biostudies-literature
| S-EPMC11357633 | biostudies-literature
| S-EPMC3824649 | biostudies-literature
| S-EPMC6939757 | biostudies-literature
| S-EPMC3797456 | biostudies-literature
| S-EPMC8093631 | biostudies-literature
| S-SCDT-EMBOJ-2020-106048P | biostudies-other
| S-EPMC9144968 | biostudies-literature